Cerus Stock Price, News & Analysis

Cerus Corporation has secured a five-year agreement with the American Red Cross to supply the INTERCEPT Blood System for Platelets. This contract aims to enhance patient access to pathogen-reduced platelets, reinforcing the Red Cross's commitment to blood safety. As the largest blood provider in the U.S., collecting over 4.6 million donations in 2021, the Red Cross will continue using Cerus' technology to meet FDA safety standards. This partnership is expected to ensure the availability of safe blood transfusions for hospitals, physicians, and patients nationwide.

Cerus Corporation (CERS) will release its first quarter 2022 financial results on May 5, 2022, post-market close. A conference call and webcast will occur at 4:30 P.M. ET to discuss the results and provide a business overview. The INTERCEPT Blood System, crucial for pathogen protection in blood components, is marketed globally, with the red blood cell system under regulatory review in Europe. The company aims to enhance blood safety and solidify its position as a global leader.

Cerus Corporation (NASDAQ: CERS) announced that CFO Kevin D. Green will participate in the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 1:30 p.m. EST. A live webcast will be accessible on the company's Investor Relations page, with a replay available for two weeks post-event. Cerus focuses on ensuring the safety of the global blood supply with products like the INTERCEPT Blood System, which is FDA-approved for platelets and plasma and under review for red blood cells in Europe. More details can be found on their website.

Cerus Corporation (CERS) reported a robust Q4 2021 with total revenues of $50.1 million, up 49% year-over-year, driven by a 41% increase in product revenues to $39.9 million. The full-year revenue reached $159.5 million, a 40% increase from 2020. The company reiterated its 2022 product revenue guidance of $157-$164 million, indicating expected growth of 20%-25%. Notably, government contract revenues surged by 90% to $10.2 million in Q4. However, net loss narrowed to $9.1 million, down from $14.4 million in Q4 2020.

Cerus Corporation (NASDAQ: CERS) will release its fourth quarter and full-year 2021 financial results on February 22, 2022, post-market close. A conference call will follow at 4:30 P.M. ET, providing insights into the company’s performance and future outlook. Investors can access the live webcast on Cerus’ Investor Relations page or by calling U.S. (866) 235-9006 or international (631) 291-4549.

Additionally, a replay will be available post-call through March 8, 2022.

Cerus Corporation (CERS) announced its participation in the upcoming BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the 11th Annual SVB Leerink Global Healthcare Conference. Vivek Jayaraman, COO, will present on February 16 at 9:00 a.m. EST, while CFO Kevin Green will participate on February 18 at 12:00 p.m. EST. The events are for BTIG clients, and webcasts can be accessed via Cerus' investor relations webpage. Cerus focuses on safeguarding the blood supply globally, offering the INTERCEPT Blood System, which has CE and FDA approvals for pathogen reduction.

Cerus Corporation (CERS) announced preliminary product revenues for Q4 2021 at $39.9 million, marking a 41% increase from Q4 2020. The full-year 2021 product revenue is expected to reach $130.9 million, exceeding previous guidance of $127-$129 million. Looking ahead, 2022 revenue is projected between $157-164 million, reflecting a growth of 20%-25%. The company also plans to expand access to INTERCEPT Fibrinogen Complex following FDA approval. Full financial results will be discussed in February.

Cerus Corporation (NASDAQ: CERS) announced that CFO Kevin D. Green will participate in the Stephens Annual Investment Conference on December 3, 2021, at 2:00 p.m. ET in Nashville, Tennessee. A live webcast will be accessible on the Cerus Investor Relations page, with a replay available for about two weeks post-event. Cerus is focused on safeguarding the global blood supply, offering technologies like the INTERCEPT Blood System, which has CE Mark and FDA approval for pathogen reduction in platelets and plasma. For details, visit www.cerus.com/ir.

On November 15, 2021, Cerus Corporation (CERS) will participate in the Stifel 2021 Virtual Healthcare Conference, featuring CEO William ‘Obi’ Greenman and CFO Kevin D. Green. The event is set for 4:40 p.m. ET, with a live webcast available on Cerus' Investor Relations page. Cerus is focused on ensuring blood safety, developing technologies like the INTERCEPT Blood System, which is approved for pathogen reduction in platelets and plasma. The company aims to lead in global blood products.